NEXI Stock - NexImmune, Inc.
Unlock GoAI Insights for NEXI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,024,972 | $-1,495,345 | $-870,285 | $-618,990 | $-436,365 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-29,192,480 | $-63,082,889 | $-53,255,782 | $-27,851,433 | $-20,885,769 |
| Net Income | $-32,344,392 | $514.18M | $-51,745,427 | $-31,638,668 | $-20,299,931 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-30.82 | $534.29 | $-56.67 | $-34.76 | $-22.53 |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Visit WebsiteEarnings History & Surprises
NEXIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 11, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 27, 2025 | — | — | — | — |
Q4 2024 | Dec 26, 2024 | — | — | — | — |
Q3 2024 | Aug 7, 2024 | — | $-1.69 | — | — |
Q2 2024 | Apr 16, 2024 | $-5.85 | $-4.99 | +14.7% | ✓ BEAT |
Q1 2024 | Feb 7, 2024 | $-5.85 | $-5.03 | +14.1% | ✓ BEAT |
Q4 2023 | Nov 17, 2023 | $-7.50 | $-9.40 | -25.3% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-7.25 | $-7.25 | 0.0% | = MET |
Q2 2023 | May 15, 2023 | $-11.25 | $-9.25 | +17.8% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-14.50 | $-16.25 | -12.1% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-16.50 | $-15.00 | +9.1% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-16.50 | $-17.25 | -4.5% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-17.75 | $-16.50 | +7.0% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-21.00 | $-17.00 | +19.0% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-16.75 | $-16.25 | +3.0% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-13.50 | $-13.50 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | $-20.25 | $-17.75 | +12.3% | ✓ BEAT |
Q1 2021 | Mar 31, 2021 | — | $-8.11 | — | — |
Q1 2021 | Feb 11, 2021 | — | $-13.32 | — | — |
Latest News
Frequently Asked Questions about NEXI
What is NEXI's current stock price?
What is the analyst price target for NEXI?
What sector is NexImmune, Inc. in?
What is NEXI's market cap?
Does NEXI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NEXI for comparison